BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biotroy Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biotroy Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07107204-2420@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:BT02: Phase 1/2 readout est. (NCT07107204)
DESCRIPTION:BT02\, phase 1/2.\nStudy: A Clinical Study of BT02 in Patients 
 With Relapsed or Refractory Hematologic Malignancies\nEstimated primary co
 mpletion: January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bt02#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07107204
URL:https://assetmemo.bio/drug/bt02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
